Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Ciforadenant Plus Ipilimumab/Nivolumab Is Safe But Does Not Boost Efficacy in Frontline ccRCC

December 16th 2025

Ciforadenant in combination with ipilimumab and nivolumab was safe and feasible but did not enhance activity in frontline ccRCC.

Denosumab Displays Tolerability, Combination Potential in AYA Osteosarcoma

December 16th 2025

R. Lor Randall, MD, FACS, discusses findings from a phase 2 study of denosumab in patients with osteosarcoma.

FDA Expands the Indications of 2 Tests to Identify Patients With HER2+ Breast Cancer Eligible for T-DXd

December 16th 2025

The FDA has expanded the indications of 2 assays to identify patients with HER2+ breast cancer for treatment with T-DXd.

FDA Grants Fast Track Designation to Muzastotug Plus Pembrolizumab in MSS mCRC

December 16th 2025

Muzastotug has been granted fast track designation by the FDA for use in combination with pembrolizumab as treatment for patients with MSS mCRC.

Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC

December 16th 2025

Venetoclax in combination with enzalutamide displayed a favorable safety profile as a treatment regimen for mCRPC.

Bezuclastinib Shows Promise in Nonadvanced Systemic Mastocytosis

December 15th 2025

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

Revumenib Shows Activity Across R/R KMT2A-Rearranged Acute Leukemia Subtypes

December 15th 2025

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Dr Jänne on Selecting a Combination Regimen in First-Line EGFR+ NSCLC

December 12th 2025

Pasi A. Jänne, MD, PhD, discusses considerations for selecting a frontline combination regimen in EGFR-mutated NSCLC.

Dr Gonzalez-Martin on the Safety of TUB-040 in Ovarian Cancer

December 12th 2025

Antonio Gonzalez-Martin, MD, discusses the key safety findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer

December 12th 2025

Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

Alpelisib Plus Fulvestrant Hits Primary PFS End Point in CDK4/6 Inhibitor–Pretreated, PIK3CA-Mutant, HR+/HER2– Breast Cancer

December 12th 2025

Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.

FDA Grants Priority Review to sBLA For Nivolumab Plus AVD in Untreated Classical Hodgkin Lymphoma

December 11th 2025

The FDA has accepted and granted priority review to the sBLA for nivolumab plus AVD in untreated adult and pediatric classical Hodgkin lymphoma.

FDA Grants Orphan Drug Designation to Risvutatug Rezetecan for SCLC

December 11th 2025

The FDA granted orphan drug designation to the B7-H3–targeted antibody-drug conjugate GSK’227 for small cell lung cancer.

Belzutifan Maintains Efficacy After a PD-(L)1 Inhibitor and Multiple VEGFR TKIs in ccRCC

December 11th 2025

Belzutifan maintained efficacy benefits vs everolimus among patients with ccRCC after at least 2 prior VEGFR TKIs.

Sacituzumab Govitecan Maintains QOL Benefit Over Chemotherapy in Previously Untreated TNBC

December 10th 2025

PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.

Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer

December 10th 2025

Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.

AJ1-11095 Receives Orphan Drug Designation From the FDA in Myelofibrosis

December 10th 2025

AJ1-11095 received orphan drug designation from the FDA in myelofibrosis.

Early Data Show Deep MRD-Negative Responses, CAR T-Cell Persistence With KLN-1010 in R/R Myeloma

December 9th 2025

The in vivo, BCMA-directed CAR T-cell therapy produced initial MRD-negative responses and persistent CAR T-cell expansion in 4 patients with relapsed/refractory myeloma.

Tagraxofusp/Azacitidine/Venetoclax Triplet Is Safe, Feasible in First-Line and R/R BPDCN

December 8th 2025

Triplet therapy with tagraxofusp/azacitidine/venetoclax led to high remission rates and had a safety profile similar to that of tagraxofusp alone in BPDCN.

Sonrotoclax Displays Activity in BTK Inhibitor–Pretreated R/R MCL

December 8th 2025

Sonrotoclax monotherapy led to an ORR of 52.4% and a CR rate of 15.5% in relapsed/refractory MCL.